drugset / Trial / NCT02666430

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

NCT02666430

Phase 3 Completed 127 enrolled Mylan Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.

Timeline

Start
2015-12
Primary completion
2017-03
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic Subcutaneous